Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity.
Human infection with Histoplasma capsulatum or Blastomyces dermatitidis is sufficiently frequent to warrant exploring the development of vaccines. This review examines the advancements that have been accomplished over the last few years. The availability of molecular tools to create recombinant antigens or mutant strains has produced a small number of useful vaccine candidates. More importantly, the studies summarized herein demonstrate that understanding the host response to a protein or mutant fungus is critical to creating a vaccine that may be useful for the immunocompromised patient.
Deepe
George S
GS
Veterans Affairs Hospital and Division of Infectious Diseases, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0560, USA. george.deepe@uc.edu
Wüthrich
Marcel
M
Klein
Bruce S
BS
D000818:Animals; D001758:Blastomyces / Q000276:immunology / Q000472:pathogenicity; D001759:Blastomycosis / Q000276:immunology / Q000517:prevention & control*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D005657:Fungal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006658:Histoplasma / Q000276:immunology / Q000472:pathogenicity; D006660:Histoplasmosis / Q000276:immunology / Q000517:prevention & control*; D007111:Immunity, Cellular / Q000187:drug effects*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics / Q000502:physiology
D005657:Fungal Vaccines; D016693:Receptors, Antigen, T-Cell, alpha-beta